0 K# v7 |/ o; ^! |' h" h! s: Y
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:/ d' f( Y, e3 t! X, g
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.3 J. S9 u8 {. d/ R+ q http://www.ncbi.nlm.nih.gov/pubmed/22968184 2 z7 A. {/ M1 t! B) F7 s6 R7 Q( s' f- m) |
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制 7 N* Y8 O' W1 Q1 r( ^http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx